

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> G01N 33/86, C12Q 1/56	<b>A1</b>	<b>(11) International Publication Number:</b> WO 96/14581 <b>(43) International Publication Date:</b> 17 May 1996 (17.05.96)
<b>(21) International Application Number:</b> PCT/SE95/01324 <b>(22) International Filing Date:</b> 8 November 1995 (08.11.95)  <b>(30) Priority Data:</b> 9403833-8      8 November 1994 (08.11.94)      SE  <b>(71) Applicant (for all designated States except US):</b> GLOBAL HEMOSTASIS INSTITUTE MGR AB [SE/SE]; P.O. Box 125, S-581 02 Linköping (SE).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> RÅNBY, Mats, Gustaf [SE/SE]; Sofiehemsvägen 29, S-907 38 Umeå (SE).  <b>(74) Agents:</b> NILSSON, Brita et al.; Oscar Grahn Patentbyrå AB, P.O. Box 19540, S-104 32 Stockholm (SE).		<b>(81) Designated States:</b> CN, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published -</b> With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. In English translation (filed in Swedish).
<b>(54) Title:</b> METHOD, REAGENT AND KIT FOR ANALYSIS OF HAEMOSTATIC ACTIVITY  <b>(57) Abstract</b>  Method of analysis of coagulative, fibrinolytic or haemostatic activity in especially blood or blood plasma from mammals, especially humans, is described. The method comprises bringing a sample, <i>in vitro</i> , into contact with fixed and preferably from their growth support detached endothelial cells or outer membranes of such cells, and detecting the resulting coagulated material and, in some cases, also lyzed coagulated material. Described are also reagents that are based on said endothelial cells and their outer membranes, and a kit for performing such a method including said reagent.		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## METHOD, REAGENT AND KIT FOR ANALYSIS OF HAEMOSTATIC ACTIVITY

### 5 FIELD OF INVENTION

The present invention pertains, in general, to the field of haemostasis or to the study of the haemostatic system of mammals, in particular humans. More specifically, it pertains to a new, simple and thereby clinically useful analytical method which allows  
10 evaluation of either coagulative or fibrinolytic activity or even total haemostatic activity in a biological fluid. Primarily, this means analysis, in a simple yet reproducible and reliable manner, of blood or blood plasma in order to detect haemophilia and/or thrombophilia. The technique according to the invention is based on contact between the biological fluid and a reagent which effects the coagulative  
15 process, after which coagulated material is detected according to prior art principles. The novelty in relation to the invention is the utilization of a reagent that highly resembles the factors that in vivo effect coagulation in a mammalian individual, which gives better possibilities than the prior art to obtain a total picture of the haemostatic activity.

20

The invention also pertains to a kit for performing this method.

### BACKGROUND OF THE INVENTION

25 Circulatory disturbances can lead to illness with bleedings or thrombi, clinical conditions which are denoted haemophilia or thrombophilia, respectively. Such disturbances may result from perturbations in the ability of the blood to coagulate or to dissolve coagulated material or from perturbations of the balance between these. Coagulum formation and coagulum dissolution are both precisely regulated  
30 processes, both of which can be regarded as composed of a driving and a restraining part. The coagulum-forming process is called coagulation and is hence a balance between pro-coagulative and anti-coagulative activities. Analogously, the

coagulum dissolving process is called fibrinolysis and displays a pro-fibrinolytic and an anti-fibrinolytic part. The balance between coagulation and fibrinolysis is denoted haemostasis, which thus comprises all processes that prevent leakage of blood from the circulatory tract and which keep these open. The two concepts circulatory  
5 disturbances and haemostatic disturbances are in this context practically synonymous.

The understanding of haemophilia and the development of effective treatments for this condition has been strongly dependent on simple global functional laboratory  
10 methods, which have revealed altered coagulative properties of blood and blood plasma from the individuals in question. The principle of these methods is to add, to blood or blood plasma, reagents that trigger coagulation, and to register the reaction time necessary for a certain coagulum formation. Abnormally slow or weak coagulum formation has been characteristic of haemophilia, and medical treatments  
15 which have normalized the analytically determined values have proved to be effective in the alleviation of the clinical symptoms of the disease.

According to the above described view on hemostasis, the outlined prior art global functional laboratory methods for the characterization of coagulative activity are  
20 primarily sensitive to pro-coagulative disturbances. The methods have, however, appeared to be fairly satisfactory for the diagnosis of haemophilia because the haemostatic disturbances involved are often localized precisely to the pro-coagulative part of haemostasis. However, the prior art global methods cannot reveal disturbances in all haemophiliacs, and they are practically of no use for  
25 thrombophilia. This may be due to the fact that the methods do not give any indication, or only slight indication, of disturbances in the anti-coagulative part of the coagulation process, and that they lack sensitivity to fibrinolytic disturbances. The lack of or the need of a more comprehensive method, useful in practice, for analyzing or detecting coagulative, fibrinolytic and haemostatic properties of blood  
30 and blood plasma, is therefore obvious. A simple and especially a more reliable method relating to global haemostasis would doubtless result in improved diagnostics, improved treatment and more efficient development of methods of

treatment, especially of thrombophilia. The present invention provides an improved global laboratory method of diagnostic analysis of coagulative, fibrinolytic or haemostatic properties of blood and blood plasma. Moreover, the method is of such nature that it is directly applicable to corresponding analysis of other biological fluids wherein such activities are present, for example synovial fluid and brain liquor.

## DESCRIPTION OF THE INVENTION

The present invention thus provides a method of analysis of biological fluid from a mammalian individual, in particular human, for the purpose of determining or analyzing coagulative activity or fibrinolytic activity in a mammalian individual or even the total or global haemostatic activity in said fluid. In other words, it is possible, according to the invention, to identify individuals having disposition for haemophilia as well as individuals having disposition for thrombophilia by using one and the same method of analysis. Moreover, this can be achieved according to the invention in a most simple manner by performing the analysis in vitro on very small amounts of sample of the biological fluid in question. This makes the method according to the invention particularly well suited for laboratory diagnostic use.

The method according to the invention is based on the surprising discovery that devitalized endothelial cells or devitalized and from their support liberated endothelial cells trigger coagulation in a biological fluid, especially in blood and blood plasma, in such a manner that haemostatic disturbances typical for both haemophilia and thrombophilia can be detected. Moreover, it has been discovered that the coagulated material, which is formed when the biological fluid is contacted with devitalized endothelial cells, can serve as a substrate for the fibrinolytic activity of the biological fluid which therefore can be analyzed and characterized according to the invention. This in turn makes it possible, as will be detailed below, to analyze and characterize a quantity that can be identified with haemostatic activity. Thus, it has been discovered that devitalized endothelial cells, and devitalized and from there their support liberated endothelial cells, possess considerable diagnostic potential with regard to haemostatic disturbances.

Nothing has hitherto been revealed about the properties of endothelial cells and their interactions with biological fluids, particularly blood and blood plasma, (see Stern et al. 1985, Proc. Natl. Acad. Sci. 82, 2523-2527 and Kirchhofer et al. J. Clin. Invest. 93, 2073-2082) that would initiate the use of these cells in in vitro laboratory diagnostic context. The generally accepted view that endothelial cells are strongly anti-coagulative should refrain a man skilled in the art from attempting to use endothelial cells in such diagnostic contexts where coagulative or fibrinolytic or haemostatic properties of a sample are to be analyzed. At least it can be established that the diagnostic potential of endothelial cells in this context has neither been conceived nor observed. As example of prior art, EP-A-538 951 can be mentioned. Therein, the difference between tissue factor and thromboplastin activity between cells from extra-cellular tissue and endothelial cells is mentioned, i.e. endothelial cells have been considered useless in the context contemplated by the present invention.

Nevertheless, according to the present invention it is shown that endothelial cells can be fixed and detached from their support, or vice versa, and that these fixed endothelial cells still possess activities of such nature that they are useful as a main component in reagents for analysis or characterization of coagulation, fibrinolysis and haemostasis in a mammalian individual. The nature of the reagent used in the method of the invention will thereby be very close to the reality in that coagulation under the influence of a system of co-operating and opposing factors are studied according to the invention in stead of some factor or a few factors disconnected from their context. The fact that detachment of the endothelial cells from the support on which they have been cultured or allowed to grow apparently does not harm the, in this context, active membrane structure, allows the present invention to utilize the effects mentioned, in a particularly advantageous way, in already existing equipment. For example, the new reagent according to the invention can be used in regular coagulation instruments as a particulate suspension or can be used to coat a solid surface to immobilize the particulate preparation. Still, the method according to the invention comprises also the case when the endothelial cells used are not detached

from their original place of growth, even though this, in many cases, means that full advantage of the surprising discovery of the activity in question of the fixed and detached cells, is not obtained.

- 5 The method according to the invention is thus a method of analysis, particularly quantitative analysis, of coagulative, fibrinolytic or haemostatic activity in a biological fluid, especially blood or blood plasma, from a mammalian individual, in particular human, wherein the characteristic feature of the method is contacting a quantity of sample of said fluid, in vitro, with fixed and preferably from their place of growth
- 10 detached endothelial cells, or outer membranes of such cells, and detecting the resulting coagulated material, preferably by measuring the time required for a certain amount of coagulum to form or by measuring the amount of coagulum formed during a certain period of time. Both before and after the coagulum-lytic activities of the sample have had the opportunity to be expressed, detection of the resulting
- 15 coagulated material can be done and, if this proves to be more advantageous, the result of the lytic processes is detected.

- More specifically an aspect of the invention is directed to a method of analysis, particularly quantitative analysis, of coagulative, fibrinolytic or haemostatic activity in
- 20 a biological fluid, especially blood and blood plasma, from a mammalian individual, especially human, wherein a quantity of a sample of biological fluid, especially blood or blood plasma, is brought into contact in vitro with fixed and preferably from their place of growth detached endothelial cells, or outer membranes of such cells, and either
- 25 a) the rate of coagulum formation or the time required for a certain amount of coagulum to form is determined, this rate or coagulation time being compared with reference values of rates and coagulation times of normal individuals, and if this rate or coagulation time is shorter than the reference values the sample of biological fluid is likely to come from an individual having disposition for thrombosis, whereas if the
- 30 rate or coagulation time is longer than the reference values then the sample of biological fluid is likely to come from an individual having disposition for bleeding, or

- b) the coagulative processes are disrupted and the amount of coagulum formed during a certain contact time is determined, the amount of coagulum being compared with reference values of amounts of coagulum of normal individuals, and if the amount of coagulum is smaller than the reference values then the sample of biological fluid is likely to come from an individual having disposition for bleeding, whereas if the amount of coagulum is greater than the reference values then the sample is likely to come from an individual having disposition for thrombosis,
- or
- c) the coagulative processes are disrupted after a certain time and an additional certain reaction time is allowed, followed by determination of the amount of dissolved coagulated material, this amount of dissolved coagulated material being compared with reference values of dissolved coagulated material of normal individuals, and if the dissolved amount of coagulated material is greater than the reference values then the sample of biological fluid is likely to come from an individual having disposition for bleeding, whereas if the dissolved amount of coagulated material is smaller than the reference values then the biological fluid is likely to come from an individual having disposition for thrombosis,
- or
- d) the coagulative processes are disrupted after a certain time and an additional certain reaction time is allowed, followed by determination of the residual amount of coagulated material, this amount of residual coagulum is compared with reference values of amounts of residual coagulum of normal individuals, and if the amount of residual coagulum is smaller than the reference values then the sample of biological fluid is likely to come from an individual having disposition for bleeding, whereas if the amount of residual coagulum is greater than the reference values then the biological fluid is likely to come from an individual having disposition for thrombosis.

When the procedural step a) or b) is performed, results pertaining to coagulative activity are obtained. When the procedural step c) is performed, results pertaining to fibrinolytic activity are obtained, and when the procedural step d) is performed results pertaining to haemostatic activity are obtained. Alternatively, the fibrinolytic,



or coagulum-lytic, activity can be identified as the difference between assay results obtained in b) and d).

5 In one embodiment of the invention, the amount of sample of the biological fluid is previously reversibly anti-coagulated blood or blood plasma, which in connection with the mentioned in vitro contact is returned to its coagulation-active state. Thus,, for exemple, the fluid, which can be blood or blood plasma, is anti-coagulated with a substance that binds  $\text{Ca}^{2+}$  ions, preferably citrate or EDTA, and the return to its coagulation-active state is accomplished by addition of excess amounts of  $\text{Ca}^{2+}$  ions. Alternatively, the fluid may be anti-coagulated with a coagulation-inhibiting substance, e.g. hirudin or heparin, and the return to the coagulation-active state is accomplished by addition of a substance which inhibits the effect of said coagulation-inhibiting substance, for exemple antibodies that inhibit the activity of hirudin or heparinase, respectively.

15

Conveniently, the analysis is performed on an amount of sample of biological fluid of maximally 1.0 mL, preferably 0.01 - 1.0 mL. Most preferably the amount of sample is maximally 0.2 mL, and the coagulation time is maximally 15 minutes.

20 In performing the procedural step b), c) or d), the coagulative processes may be disrupted by the addition of a coagulation-inhibiting substance, which preferably is chosen from the group consisting of hirudin and heparin but also  $\text{Ca}^{2+}$  ion complexing agents such as citrate, oxalate or EDTA are possible.

25 In performing the procedural step a) or b), the analysis may be performed in the presence of a fibrinolysis-inhibiting substance, which preferably is chosen from the group of 6-amino-hexanoic acid and antibodies against tPA and uPA.

30 The result of performing the procedural step a), can be obtained by detecting coagulated material by means of measuring changes in the optical or rheological properties of the reaction mixture, preferably changes in light transmission or viscosity.

The results of performing the procedural step b), c) or d) can be obtained by detecting coagulated material by measuring some component or degradation product of the coagulated material, preferably fibrin or thrombocytes. Conveniently, results in  
5 this regard are obtained by measuring the amount of fibrin via its enzymatic degradation, preferably by plasmin, to soluble degradation products, which are measured with immunological technique. So, for exemple, said degradation products may be measured with an immunological technique which is specific for D-dimer fragments, or the amount of thrombocytes associated with fibrin may be  
10 measure by flow cytometry after enzymatic degradation of the fibrin.

Another aspect of the invention is directed to a reagent for the analysis of coagulative, fibrinolytic or haemostatic activity of a biological fluid, especially blood or blood plasma, from a mammalian individual, especially human, which reagent is  
15 composed of suspended or support-attached endothelial cells or outer membranes from such cells.

In an embodiment of of this aspect of the invention, the endothelial cells or their outer membranes are from an individual of the same species as the individual whose  
20 biological fluid is to be analyzed, preferably from the same individual and most preferably from the part of the body which is subjected to said analysis.

In another embodiment, the endothelial cells or their outer membranes are immobilized on a solid phase. In order to stabilize the active surface structures,  
25 polyethylene ethers or polysaccharides can be covalently bound to the outer membranes of the endothelial cells.

Yet another aspect of the invention is directed to a kit for performing a method of analysis of coagulative, fibrinolytic or hemostatic activity in a biological fluid,  
30 especially blood or blood plasma, from a mammalian individual, especially human, which kit comprises , as a coagulation reagent, a reagent according to the invention and instructions for performing the method.

According to the invention, it has been shown that devitalized (other commonly used denotation; fixed) or devitalized and detached from their support (other commonly used denotation; suspended) endothelial cells can be used to characterize

5 coagulative, fibrinolytic and hemostatic activity of biological fluids, especially blood and blood plasma, and that this can be accomplished in a diagnostically valuable manner, i.e. so that individuals with circulatory diseases can be differentiated from normal individuals. Functions typical for the living endothelial cell, such as excretion, endocytosis and modifications of outer membrane structures, are obviously not

10 necessary in order for endothelial cells to trigger activities in biological fluids that make meaningful diagnosis possible. From this it is obvious that also isolated outer membranes from endothelial cells can be used in practising the invention. Thus, the use of such outer membranes does not represent any deviation from the spirit of the invention, and in this context even synthetically manufactured structures

15 characteristic for the surface of endothelial cells may be contemplated. In other words, the expression "outer membranes of such cells" should be interpreted broadly and it encompasses all attempts to (also synthetically) arrive at a membrane-like structure that triggers the same or similar activities in biological fluids, especially blood and blood plasma, as fixed or fixed and suspended endothelial cells.

20

The fixed endothelial cells used in the method according to the invention, can be obtained from different sources and can be prepared in different ways without deviating from the original idea of the invention. Endothelial cells can, for example, be obtained from cultured cells which in accordance with known methodology have

25 been detached from the interior surface of umbilical cord veins. Placenta is another possible source of endothelial cells as are established cell lines of transformed endothelial cells. It should be understood that an effective preparation according to the invention, of fixed or fixed and from their support detached endothelial cells, does not necessarily need to be totally homogeneous. It is sufficient that a main

30 constituent of a cell preparation according to the invention is endothelial cells.

Preferably such endothelial cells are chosen that are from an individual of the same species as the individual from whom the biological fluid is obtained. More preferably the endothelial cells are from the same individual and most preferably from the part of the body which is subject to analysis according to the invention. Choosing  
5 endothelial cells from the same individual as from whom the sample of biological fluid is obtained would allow detection also of circulatory disturbances that stem from abnormalities of this individual's endothelial cell structures that together with this individual's biological fluid express disturbances in coagulative, fibrinolytic and/or hemostatic activity.

10

In the preparation of endothelial cells from cultures of such cells, it is possible to detach these cells from the support on which they grow, so that a mainly monodisperse suspension is obtained. The cells can, for instance, be detached by citrate or an other substance that binds  $\text{Ca}^{2+}$  ions and can thereafter be fixed. Other  
15 methods for detaching the endothelial cells, e.g. by use of EDTA, are also within the scope of the invention. If the cells are detached from their support with the aid of enzymes, it may be necessary to culture the cells for some time before they are fixed, in order to allow necessary surface structures to reform.

20 Different methods for fixation of cells are certainly previously known in the prior art. These methods are applicable also in the present case, but preferably in the method according to the invention the endothelial cells are devitalised or fixed with substances chosen from the group of formalin and STF™ fixation solution.

25 The invention is nether restricted to the case where the cells are at first fixed and thereafter detached from their support. The reverse course of action is fully possible within the scope of the invention.

Specific analysis of coagulative, fibrinolytic or haemostatic activity is possible  
30 according to the invention but may require additions of coagulation-inhibiting or fibrinolysis-inhibiting substance, which will be described in detail below.

As preferred examples of coagulation-inhibiting substances hirudin and heparin can be mentioned, and as preferred examples of fibrinolysis-inhibiting substances 6-amino-hexanoic acid and antibodies against tPA and uPA can be mentioned.

- 5 A considerable advantage with regard to the use of fixed endothelial cells according to the invention, is that these can be utilized in the form of a suspension, preferably a water-based suspension, which enables the use of equipment for detection of coagulation existing on the market. As examples of such equipment, coagulation instruments operating with liquids or suspensions and wherein detection of coagulum  
10 formation most often is performed photometrically, may be mentioned.

The in vitro contact between the fixed endothelial cells, or outer membranes, and the biological solution is, however, not restricted to the use of suspensions but can be accomplished by using other principles known per se. For example, the contact can  
15 be accomplished with endothelial cells or outer membranes immobilized on a solid phase, preferably of the micro test plate type.

Immobilization on the solid phase can preferably be accomplished via binding of biotin to the endothelial cells or outer membranes, and thereafter coupling to the  
20 surface of the solid phase by means of biotin-binding substances, preferably streptavidin.

According to yet another preferred embodiment of the method according to the invention, preparations of endothelial cells, preferably suspended, or corresponding  
25 outer membranes, with increased stability and homogeneity are obtained in case the endothelial cells are treated with reactive compounds that covalently bind hydrophilic substances to the outer membrane structures of the cells. As preferred examples of such stability- and homogeneity-improving compounds polyethylene ethers and polysaccharides may be mentioned. Thus, such improved stability and homogeneity  
30 are extremely valuable in a method of the present kind, wherein the analysis is dependent on reasonably stable reagents.

Coagulated material that results from performing the method according to invention, is preferably detected by means of measuring changes in the optical or rheological properties of the reaction mixture, especially in case the use of cells in suspension is involved. Preferably, this concerns changes in light transmission and viscosity,  
5 respectively.

Coagulated material can according to another embodiment be detected by means of measuring changes in the interactions of the reaction mixture with magnetic, electric or electromagnetic fields. This methodology is particularly suitable for working with  
10 cells immobilised on a solid phase.

Coagulated material is preferably detected via the components it contains or is made up of, particularly fibrin and thrombocytes.

15 The amount of fibrin can preferably be measured by enzymatic degradation of the same, preferably by plasmin, to soluble degradation products which are measured with immunological technique. A preferred such technique is a technique specific for D-dimer fragments.

20 Another preferred embodiment of the invention measures the amount of thrombocytes associated to the thrombocytes, for example by flow cytometry. This can be accomplished after the coagulum has been enzymatically degraded, i.e. has been lyzed.

25 As indicated above, the method according to the invention is primarily intended for analysis of blood and blood plasma but is in no way restricted to this and can be applied in any instance where activities of the corresponding type exist.

For the analysis to be useful in practice in clinical contexts, this implies that, in the  
30 method, the use is made of previously reversibly anti-coagulated blood or blood plasma which is returned to the coagulation-active state in close connection with the

contacting in vitro which, according to the invention, is performed with fixed endothelial cells or corresponding active components of these.

One preferred embodiment involves blood or blood plasma that has been anti-  
5 coagulated with substances that bind  $\text{Ca}^{2+}$  ions, preferably citrate or EDTA, and that the return to the coagulation-active state is accomplished by addition of  $\text{Ca}^{2+}$  ions in excess.

Another interesting embodiment requires that the blood or blood plasma is anti-  
10 coagulated with a coagulation-inhibiting substances of hirudin or heparin type and that the return to the coagulation-active state is accomplished by addition of agents that inhibit the effects of the anti-coagulative substances in question, preferably antibodies, that neutralize the activity of hirudin, and heparinase, respectively, that degrades heparin into inactive saccharides.

15

For a method of clinical laboratory utility it is moreover required that it must be operable on small quantities of sample. This requirement is fulfilled in the present case, since the method according to the invention can be performed on such small amounts of sample. According to one preferred embodiment of the invention this  
20 means that the analytical method is performed on an amount of sample that is smaller than 1.0 mL, preferably 0.01-1.0 mL.

For laboratory diagnostic utility, especially on larger scale, it is furthermore required that the analytical method should not be excessively extended in time. Coagulative  
25 activity may according to the invention be determined in less than 15 minutes and fibrinolytic and haemostatic activity within 90 minutes.

The invention also pertains to a kit for performing an analytical method of the type defined above, the characterizing feature of said kit being that it contains a  
30 coagulation reagent comprising the above mentioned endothelial cells or outer membranes of these, and instructions disclosing how the method is to be performed.

**DETAILED DESCRIPTION OF THE INVENTION**

The invention will be further illustrated below by means of a number of concrete practical examples, which however do not in any way restrict the scope of the invention. Before these are presented in detail, a short background of the methods and materials used will be given as follows.

Methods which today are commonly used for laboratory detection of coagulative properties of blood and blood plasma are denoted activated prothrombin time, APTT, prothrombin time, PT, and prothrombin complex time, PTK. These methods are based on the use of one or two reagents, which are mixed with the sample of blood or blood plasma, which is thereby coagulated. The speed with which the reaction mixture coagulates constitutes the assay response. Often time in question is measured from the moment of reagent addition up to a certain coagulum formation. This is detected by measuring a certain change in the optical properties of the reaction mixture or a certain change in its rheological properties.

The analyses are often performed on samples that are anti-coagulated by addition of citrate or other substances that bind  $\text{Ca}^{2+}$  ions, which are necessary for the coagulation processes. The reagents contain  $\text{Ca}^{2+}$  ions which restore the coagulative ability of the samples. If non-anti-coagulated samples are to be analyzed, the reagents need not contain  $\text{Ca}^{2+}$  ions as sufficient amounts of these are present in the blood sample.

The APTT reagent contains silica particles, and the PT- and PTK-reagents contain tissue factor preparations. Both of these reagents contain phospholipids.

With the above described generally used methods, blood and blood plasma from individuals without circulatory disturbances display normal coagulation times while samples from haemophiliacs display prolonged coagulation times. Samples from thrombophiliacs, almost without exception, display normal coagulation times.



According to one aspect of the method according to the invention, individuals without circulatory disturbances display normal coagulation times, while individuals with haemophilia often display abnormally long coagulation times and individuals with thrombophilia in many cases display abnormally short coagulation times.

5

In one embodiment of the procedure according to the invention, a reagent composed of fixed endothelial cells suspended in aqueous solution containing  $\text{Ca}^{2+}$  ions is used. When this reagent is mixed with blood or blood plasma anti-coagulated with citrate, longer than normal coagulation times are obtained for most haemophiliacs and shorter than normal for many thrombophiliacs. The coagulation times are a measure of the coagulation activity of the blood plasmas. With an identical method coagulation activity can in a similarly advantageous manner be determined for blood and other biological fluid such as synovial fluid and liquor.

10

15

Coagulative activity of anti-coagulated blood, blood plasma or other biological fluid can be analyzed and characterized also with other embodiments of the method according to the invention. According to one such embodiment, an anti-coagulated sample of the biological fluid is added to small containers, e.g. wells of micro test plates, the surface of which carry fixed endothelial cells. Once the sample has been returned to a coagulative state by the addition of substances that neutralize the anti-coagulative effect, the coagulative processes are allowed to proceed for a certain time after which they are halted by addition of coagulation-inhibiting substances such as hirudin or heparin. The amount of coagulated material is thereafter measured.

20

25

Either the amount of fibrin or the number of thrombocytes in the coagulated material is measured. The amount of fibrin can be measured by enzymatically degrading this to soluble degradation products, followed by measurement of the amount of these by immunological techniques. The number of thrombocytes in the coagulated material can be determined, e.g. with flow cytometry, after the thrombocytes have been liberated from the coagulated material by enzymatic degradation of the same. It should be mentioned that, if the fibrinolytic activity of the sample is considerable, disturbances of the analysis of coagulative activity can be avoided by addition of fibrinolysis-inhibiting substances to the sample prior to analysis. The fixed

30

endothelial cells on the inner surface of the reaction vessel can either be cultured on this site or, which is more practical and better exploits the possibility of the invention, be immobilized thereon from preparations of fixed and from their support detached endothelial cells.

5

The invention also allows for analysis of the fibrinolytic activity of the sample solution. For this purpose the coagulated material is first allowed to form under a certain time. Thereafter, the reaction is stopped by addition of coagulation-inhibiting substances, e.g. EDTA, hirudin or heparin, after which sufficient time is allowed for the results of the fibrinolytic activity of the sample to become measurable as increase of the amount of fibrin degradation products. It is pointed out that the fibrinolytic activity in a sample of biological fluid often is unstable. This can be caused by inhibitory activities, particularly plasminogen activator inhibitor type 1 (PAI-1), and can require special sample collection and sample handling techniques. Thus, for example, the pH of the sample can be immediately reduced to between 5.8 and 6.0 (see Ranby et al 1989, Thromb Haemostas 62, 917-922) to prevent reaction between tPA and PAI-1. For analysis according to the invention of such acidified samples, sufficient amounts of pH-raising substances may be added in order to avoid hampering of the coagulative and fibrinolytic processes. Correct assessment of the fibrinolytic activity may also require addition of substances that prevent said reaction after the pH has been neutralized. An example of such a substance is inhibitory antibodies towards PAI-1.

An analytical method that resembles the latter application of the invention enables an assay response that can be identified with haemostatic activity. Hereby the coagulative activity is first allowed to express for a certain time during which an amount of coagulated material in proportion to the coagulative activity is formed, whereupon the coagulative processes are stopped by the addition of a coagulation-inhibiting substance. Thereafter, the fibrinolytic activity is allowed to act under a sufficient time for creation of a measurable reduction of the amount of coagulated material. The amount of coagulated material that then remains constitutes a measure of the balance between coagulation and fibrinolysis, i.e. the hemostatic

activity. The amount of coagulated material is measured as the amount of fibrin and/or as the number of coagulum-associated thrombocytes, as previously described.

- 5 The method according to one embodiment of the present invention is based on the use of reagents that are mixed with samples in principally the same manner as in the analysis according to the methods of APTT, PT and PTK. The coagulation times are registered in the same manner as in these methods.

## 10 EXAMPLES

### MATERIALS

Human endothelial cells from umbilical cord were prepared from 30 to 40 cm long umbilical cords from full term foetus. The umbilical cords were obtained from the  
15 maternity ward, the University Hospital of Linköping, Sweden. Prior to preparation, the umbilical cords were stored for not more than 24 hours at 2—6°C in sterile PBS (phosphate buffered saline) with penicillin and gentamycin. During preparation the umbilical cord vein was, rinsed with about 50 mL of sterile PBS containing penicillin and gentamycin, filled with cell culture medium A (Dulbeccos Minimal Essential  
20 Medium, 1% non-essential amino-acids, 2% 200 mM L-glutamine, 1.2% 100 mM/20 IU/mL oxalo-acetic acid/insulin, 12% foetal calf serum and 0.1% penicillin-streptomycin) containing 500 mg/L collagenase, closed at both ends with Péans and incubated for 15 minutes at 37°C, whereupon it was massaged for 2 minutes. The contents of umbilical vein including 25 mL of rinse (medium A) were transferred to a  
25 50 mL test tube, which was centrifuged for 5 minutes at about 500 xg for sedimentation of the endothelial cells. The supernatant was discarded and the endothelial cells suspended in 10 mL of medium A. The endothelial cells were again allowed to sediment by centrifugation for 5 minutes at 500 xg, after which the supernatant was discarded and the cells were suspended in 5 mL of medium A and  
30 transferred to a 23 cm<sup>2</sup> cell culture flask with gelatin treated bottom surface. This primary culture was incubated for 2 to 4 days at 37°C in an atmosphere containing 5% CO<sub>2</sub>. When the cells had developed into a confluent mono-layer, verified

microscopically, they were passaged. The passage indicates that the cell culture medium was discarded and the cells detached from their support by treatment with minimal amount of 10 g/L trypsin dissolved in 0.15 M NaCl and 5 mM EDTA. The detached endothelial cells were suspended in 10 mL of medium A and seeded into  
5 two cell culture flasks each with a gelatin-treated bottom surface of about 23 cm<sup>2</sup>. At confluence, after 2 to 4 days of culture, the cells were passaged a second time and seeded out in four cell culture flasks with gelatin-treated bottom surface of 23 cm<sup>2</sup> each. For some experiments, the endothelial cells were seeded out in about 50 micro test plate wells with gelatine treated bottom surfaces. When these cells, in the  
10 following called HUVEC (human umbilical vein endothelial cells), within 2 to 4 days formed a confluent mono-layer, they were used in the examples below.

Gelatin treatment of cell culture flasks and micro test plate wells was performed in such manner that the bottom surfaces were covered with 0.2% gelatin in water,  
15 incubated for 15 minutes, emptied of excess and allowed to air dry.

For Example 1 were used: suspended devitalized (fixed) endothelial cells, that were obtained by washing the HUVEC cells in one cell culture flask with PBS and detaching them from their supporting place of growth by 15 minute incubation at  
20 37°C in 4 mL of 0.1 M (Na<sup>+</sup>) citrate buffer pH 7.3 with an addition of 0.05 mL of 20 mM TM-PEG.

For Examples 4 and 5 were used: suspended fixed endothelial cells, to which biotin was conjugated. These were obtained by incubating HUVEC in one 23 cm<sup>2</sup> cell  
25 culture flask for 30 minutes at 37°C with 2 mL of 21 mM Hepes buffer pH 8.2 with 105 mM sodium citrate and 2 mM CaCl<sub>2</sub> with an addition of 0.05 mL of TM-PEG and 0.05 mL of 2 mg/mL of NHS-biotin. The cells were detached with a small cell rubber policeman. The so suspended cells were fixed for 30 minutes at room temperature by the addition of 4 mL of STF fixation solution (se below) and washed by three fold  
30 repeated centrifugation and re-suspension in 0.02 M Hepes buffer pH 7.5 with 0.1 M NaCl. Suspended, fixed, biotin conjugated HUVEC were immobilized on the surface of streptavidin-treated micro test plate wells (Labsystems product 95029290) by the

addition to each well of about 4,000 cells suspended in 0.1 mL of 0.02 M Hepes buffer with 0.1 M NaCl and incubated for 18 hours at room temperature.

For Examples 2 and 3, HUVEC cultured in micro test plate wells were used. They  
5 were washed two times in PBS and devitalized by addition of 0.1 mL of 0.1% formalin in PBS per well and incubated for 10 minutes at room temperature with subsequent twice repeated wash with 0.2 mL PBS.

Samples of blood plasma were obtained from the Laboratory of Clinical Chemistry,  
10 University Hospital of Linköping with generous support of Dr. Tomas Lindahl. Samples with known APTT- and PTK-values were obtained within 4 hours of routine analysis with the reagents and instruments used by the laboratory during June 1994. The same laboratory also generously supplied citrate anti-coagulated samples from  
15 individuals without known haemostatic disorders, i.e. from healthy (normal) individuals. These samples from patients and normal individuals were stored at -70°C for a maximum of 5 months prior to use.

Reagents for the determination of D-dimer (a degradation product of fibrin) with  
ELISA technique, 1241 TintElize D-dimer, and latex technique, 150707 Minutex D-  
20 dimer, were obtained from Biopool AB, Umeå, Sweden.

tPA, tissue plasminogen activator with single-chain structure, single-chain tPA,  
product 122101 from Biopool AB, was dissolved in 0.5 M (Na<sup>+</sup>) Hepes-buffer pH 8.5  
to a concentration of 3,000 IU/mL.

25

Hirudin, product 53000, was obtained from American Diagnostics Inc., Greenwich,  
CT. Hirudin was dissolved in H<sub>2</sub>O to a concentration of 100 ATu/mL.

Heparin, 100 IU/mL for injectional use, was obtained from Løvens kemiske fabrik,  
30 Ballerup, Denmark.

STF (Streck Tissue Fixative) containing diazolidinyl-urea, 2-bromo-2-nitro-propane-1,3-diol, zinc sulphate and citrate, was obtained as ready to use solution from Streck Laboratories Inc., Omaha, NE, USA.

- 5 TM-PEG (metoxypolyethylene-glycol-tresylate), product M-3038, was obtained from Sigma Chemical Company, St. Louis, MO, USA.

NHS-LC-biotin (sulphosuccinimidyl-6-(biotiamido)hexanoate), product 21335, was obtained from Pierce, Rockford, IL, USA.

10

NaCl, CaCl<sub>2</sub>, Hepes, citric acid, formalin and 6-amino-hexanoic acid were of high commercial quality. Water of high purity was obtained from an apparatus employing ion-exchange and reversed osmosis serviced by the Department of Clinical Chemistry, University Hospital Linköping.

15

#### EXAMPLE 1

The invention was practised for analysis of coagulative activity with a protocol resembling a one-step prothrombin analysis according to Quick, wherein 1 volume of  
20 citrate anti-coagulated plasma was mixed with one volume of thromboplastin reagent containing CaCl<sub>2</sub> and registration of coagulation time was performed.

This experiment utilized a commercial Quick reagent, 50220 Thromboplastin from Biopool AB, Umeå, composed of a suspended extract from delipidated rabbit brain  
25 tissue. A corresponding reagent according to the invention was HUVEC reagent 1, which contained  $0.2 \times 10^6$  cells/mL of suspended fixed HUVEC in 50 mM Hepes buffer pH 7.3 containing 15 mM CaCl<sub>2</sub>, 30 g/L PEG 6000, 30 g/L BSA and 2 g/L Triton X-100. The analyses were performed with a coagulation instrument with photometric detection of coagulum formation, Coagulator 4, Behnk Elektronik, with  
30 0.15 mL of sample and 0.15 mL of reagent, both temperature equilibrated at 37°C.

The following citrate anti-coagulated samples were analyzed:

Pooled plasma from normal individuals (NP) and NP diluted 1:2 (NP50%) and NP 1:4 (NP25%) with a barbiturate buffer with citrate and NaCl (Tampon pour SPA,

Diagnostica Stago, Franconville, France). Moreover the following were analyzed: a

- 5 plasma sample with a PTK-value below 25% (PTK<25%) and a plasma sample (TRBP) from a thrombotic patient. The plasma sample PTK<25% was pooled from individuals treated with vitamin-K antagonists who according to analysis performed during April-May 1994 by the Laboratory for Clinical Chemistry, University Hospital Linköping, showed PTK-values of less than 25%. The results of the analysis with
- 10 Quick-reagent and HUVEC-reagent 1 are depicted in the table below, where the results have been placed in order of precedence according to their coagulation times and with the coagulation time in seconds given within parenthesis.

	Quick-reagent		HUVEC-reagent 1
15			
	NP (12.9)	TRBP (214.1)	
	TRBP (13.4)	NP (223.7)	
	NP50% (17.1)	NP50% (282.6)	
	PTK<25% (23.1)	NP25% (383.2)	
20	NP25% (25.6)	PTK<25% (459.4)	

It may especially be noted that TRBP has a longer coagulation time than NP in analysis with the Quick-reagent, while TRBP has a shorter coagulation time than NP with analysis according to the invention, HUVEC-reagent 1.

25

A plasma sample from a thrombophilic thus displays a shortened coagulation time in analysis according to the invention. This is not the case with conventional analysis. Diluted normal plasma as well as pooled plasma with long coagulation times according to other conventional method (PTK) display prolonged coagulation

30 times both with analysis according to the invention and with conventional Quick-methodology. However, analysis according to the invention seems to more clearly distinguish PTK<25% than is the case with the Quick-reagent. To summarize, in the

displayed experiment, analysis according to the invention gives more relevant diagnostic information about thrombophilia than does conventional analysis, and at least as good information on haemophilia.

- 5 For purposes of confirmation, the same thrombotic plasma (TRBP) and the same pool of normal plasma (NP) were analyzed on a later occasion, and then with another HUVEC-reagent and another commercial preparation of thromboplastin reagent (IL Test PT-fibrinogen, product 97567-10, Instrumentation Laboratories, Milano, Italy). The analysis according to the invention was performed with HUVEC-reagent 2 and  
10 HUVEC-reagent 3, which differed only in that they contained  $0.23 \times 10^6$  cells and  $0.46 \times 10^6$  cells/mL, respectively. The experiment with HUVEC-reagent 3 was performed in duplicate in the same instrument channel. Other experimental details were identical to those detailed above. The following results were obtained with the coagulation times denoted in seconds.

15

	Quick-reagent	HUVEC-reagent 2	HUVEC-reagent 3
NP	12.3	381.0	436.8 and 438.9
20 TRBP	12.6	277.5	208.4 and 236.6

Hereby confirmation was obtained, that coagulation analysis according to the invention can differentiate the plasma from a thrombotic patient from that of a normal individual in a case where conventional analysis is without diagnostic effect.

25

## EXAMPLE 2

Quantitative analysis of coagulative activity according to the invention is here applied on citrate anti-coagulated plasma from 10 patients referred to the Department of  
30 Clinical Chemistry, University Hospital Linköping, for investigation concerning cause of thrombotic disease and on the same type of samples from 10 healthy individuals, i.e. individuals who have never been afflicted with thrombotic disease.



In the analysis, a sample of size 0.10 mL was added to a micro test plate well, the bottom surface of which was covered with a confluent layer of fixed HUVEC. The reaction was started by addition of 0.010 mL of 0.5 M  $\text{CaCl}_2$  and allowed to proceed 5 minutes at room temperature under agitation on a shaking apparatus with circular eccentric movement, 1 mm eccentricity and 200 revolutions per minute. The reaction was stopped by addition of 0.010 mL of 20 ATu/mL of hirudin. The wells were emptied of their contents and washed three times with 0.25 mL of 0.15 M NaCl. Cell-associated fibrin was dissolved with 0.1 mL of human serum with 300 IU/mL of tPA which was allowed to act for 20 minutes at room temperature after which the amount of D-dimer in the serum was determined by ELISA. The following results, presented in order of precedence according to increasing content of D-dimer, were obtained:

	Thrombotic patients	Healthy individuals
	D-dimer (ng/mL)	D-dimer (ng/mL)
	75	73
5	77	78
	77	88
	83	89
	215	99
	366	119
10	577	179
	952	193
	1849	467
	2553	470

- 15 Four of the 10 thrombotic patients displayed higher, three considerably higher, amounts of fibrin associated with endothelial cells than any of the healthy individuals, when blood plasma from these were analyzed according to the invention. Statistical analysis also showed that the groups most probably differed from each other:  $p < 0.05$  according to one-tailed t-test. Analysis according to the invention of coagulative
- 20 activity according to this example displays some of the diagnostic possibilities of the procedure.

### EXAMPLE 3

- 25 Quantitative analysis of coagulative activity according to the invention with the same protocol as in Example 2 was performed on seven blood plasma samples anti-coagulated with citrate. These samples had been analyzed less than 2 hours earlier on May 18 1994 according to PTK and APTT by the Laboratory of Clinical Chemistry, University Hospital Linköping. The results for these seven samples are shown below
- 30 in order of precedence according to their PTK-times. PTK-values in percent are given within parentheses. D-dimer according to the invention.

	PTK (s)	APTT (s)	D-dimer (ng/mL)
5	19.4 (145)	35.3	368
	24.1 (91)	45.3	296
	25.0 (84)	31.7	334
	29.7 (59)	39.7	198
	31.0 (54)	47.3	195
10	44.9 (29)	33.4	149
	59.1 (20)	48.5	130

Linear regression analysis shows that coagulation activity according to the invention shows that good negative correlation with PTK-times and similar good positive correlation with PTK-values in percent. A negative correlation with APTT-times is also evident.

This result indicates that coagulation analysis according to the invention can find use in diagnostic contexts where PTK- and APTT-analyses are used, i.e. in the identification of individuals with bleeding tendencies and in guiding and monitoring of substitution therapy for haemophiliacs and therapy for thrombosis prophylaxis with oral anti-coagulants (warfarin) or subcutaneous anti-thromboticum (heparin).

The correlation between analysis according to the invention and PTK and APTT are both better than that between PTK and APTT. This highlights the over-all, global, character of the analysis according to the invention.

#### EXAMPLE 4

Quantitative analysis of coagulative activity according to the invention, but with a protocol that differs in several details from that of Example 3, was applied to blood plasma anti-coagulated with citrate from four thrombotic patients and one healthy

individual. According to this protocol, 0.10 mL of plasma was added to micro test plate wells coated with streptavidin with attached devitalized fixed biotin-conjugated endothelial cells or, as control, to similar wells but without cells. The coagulation reaction was initiated by addition of 0.025 mL of 0.15 M  $\text{CaCl}_2$  and was stopped by 0.025 mL of 100 IU/mL heparin. The amount of fibrin formed was determined quantitatively by addition of 0.025 mL of 3000 IU/mL of tPA, which under 20 minutes was allowed to process formed fibrin into soluble degradation products. These were measured as D-dimer by ELISA.

- 10 The results of the analysis, D-dimer in ng/mL, are presented below, where the value for the well containing endothelial cells is denoted "with HUVEC" and the control well "without HUVEC". The difference is given as "with-without":

	with HUVEC	without HUVEC	with-without
15 Thrombotic patient 1	188	142	46
Thrombotic patient 2	933	140	853
Thrombotic patient 3	2836	174	2662
Thrombotic patient 4	3597	52	3545
Healthy individual	2487	227	2260

25

- In this example two of the four thrombotic patients (patient 3 and patient 4) displayed greater fibrin deposit on the endothelial cells than the healthy individual. Thrombotic patient 1 displayed markedly low D-dimer development although fibrin deposition was verified microscopically. Perhaps this is a thrombotic patient with reduced ability to degrade fibrin in spite of high levels of plasminogen activator.
- 30

**EXAMPLE 5**

Quantitative analysis of fibrinolytic activity according to the invention was demonstrated with a series of five blood plasma samples from a healthy individual, to which small volumes of concentrated tPA solution was added so that the final addition of tPA activity was 0, 0.73, 2.9, 11.7, and 46.7 IU/mL. Of these tPA enriched plasmas, 0.10 mL was added to micro test plate wells with attached endothelial cells of the same kind as was used in Example 4. A limited amount of fibrin was formed during 7 minutes upon addition of 0.025 mL of  $\text{CaCl}_2$ .

- 10 The fibrin formation was stopped by addition of 0.025 mL of 100 IU/mL of heparin, after which the fibrinolytic reactions were allowed to continue for an additional 60 minutes. The amount of fibrin degradation products thus formed was used as a measure of the fibrinolytic activity and was determined as D-dimer in the well contents by ELISA. The results were the following:

15

Sample	added tPA (IU/mL)	D-dimer (ng/mL)
A	0	41
B	0.73	42
20 C	2.9	45
D	11.7	317
E	47	3640

- 25 The example shows that analysis according to the invention can be used for analysis of fibrinolytic activity. Plasma with high levels of tPA display high levels of D-dimer.

## CLAIMS

- 5 1. Method of analysis, particularly quantitative analysis, of coagulative, fibrinolytic or haemostatic activity in a biological fluid, especially blood or blood plasma, from a mammalian individual, in particular human, characterized in that a quantity of sample of said biological fluid is brought into contact in vitro with fixed and preferably from their place of growth detached
- 10 endothelial cells, or outer membranes of such cells, and either
- a) the rate of coagulum formation or the time required for a certain amount of coagulum to form is determined, this rate or coagulation time being compared with reference values of rates and coagulation times of normal individuals, and if this rate
- 15 or coagulation time is shorter than the reference values the sample of biological fluid is likely to come from an individual having disposition for thrombosis, whereas if the rate or coagulation time is longer than the reference values then the sample of biological fluid is likely to come from an individual having disposition for bleeding, or
- 20 b) the coagulative processes are disrupted and the amount of coagulum formed during a certain contact time is determined, the amount of coagulum being compared with reference values of amounts of coagulum of normal individuals, and if the amount of coagulum is smaller than the reference values then the sample of biological fluid is likely to come from an individual having disposition for bleeding,
- 25 whereas if the amount of coagulum is greater than the reference values then the sample is likely to come from an individual having disposition for thrombosis, or
- c) the coagulative processes are disrupted after a certain time and an additional certain reaction time is allowed, followed by determination of the amount of
- 30 dissolved coagulated material, this amount of dissolved coagulated material being compared with reference values of dissolved coagulated material of normal individuals, and if the dissolved amount of coagulated material is greater than the

reference values then the sample of biological fluid is likely to come from an individual having disposition for bleeding, whereas if the dissolved amount of coagulated material is smaller than the reference values then the biological fluid is likely to come from an individual having disposition for thrombosis,

5 or

d) the coagulative processes are disrupted after a certain time and an additional certain reaction time is allowed, followed by determination of the residual amount of coagulated material, this amount of residual coagulum is compared with reference values of amounts of residual coagulum of normal individuals, and if the amount of  
10 residual coagulum is smaller than the reference values then the sample of biological fluid is likely to come from an individual having disposition for bleeding, whereas if the amount of residual coagulum is greater than the reference values then the biological fluid is likely to come from an individual having disposition for thrombosis.

15 2. Method according to Claim 1, characterized in that said quantity of sample of said fluid is previously reversibly anti-coagulated blood or blood plasma, which in connection with said contact in vitro is returned to coagulation active state.

20 3. Method according to Claim 2, characterized in that said quantity of sample of said fluid is blood or blood plasma that has been anti-coagulated with a substance that binds  $\text{Ca}^{2+}$  ions, preferably citrate or EDTA, and that said return to coagulation active state is accomplished by addition of an excess of  $\text{Ca}^{2+}$  ions.

25 4. Method according to Claim 2, characterized in that said quantity of sample of said fluid is blood or blood plasma that has been anti-coagulated with a coagulation-inhibiting substance, preferably hirudin or heparin, and that said return to coagulation active state is accomplished by addition of a substance which inhibits the activity of said coagulation-inhibiting substance, preferably antibodies that neutralize the activity of hirudin and heparinase, respectively.

30

5. Method according to any one of the preceding Claims, characterized in that the analysis is performed on a quantity of biological fluid of maximally 1.0 mL, preferably 0.01-1.0 mL.
- 5 6. Method according to Claim 1 b), c) or d), characterized in that, during the analysis, the coagulative processes are disrupted by the addition of a coagulation-inhibiting substance, which preferably is selected from the group consisting of hirudin and heparin.
- 10 7. Method according to Claim 1 a) or b), characterized in that the analysis is performed in the presence of a fibrinolysis-inhibiting substance, which preferably is selected from the group of 6-amino-hexanoic acid and antibodies against tPA and uPA.
- 15 8. Method according to Claim 1 a), characterized in that coagulated material is detected by means of changes in optical or rheological properties of the reaction mixture, preferably changes in light transmission or viscosity.
9. Method according to Claim 1 b), c) or d), characterized in that coagulated  
20 material is detected by measuring some component or degradation product of the coagulated material, preferably fibrin, degradation products of fibrin or thrombocytes.
10. Method according to Claim 9, characterized in that the amount of fibrin is measured via its enzymatic degradation, preferably with plasmin, to soluble  
25 degradation products, which are measured with immunological technique.
11. Method according to Claim 10, characterized in that said degradation products are measured with immunological technique specific for D-dimer fragments.
- 30 12. Method according to Claim 9, characterized in that the amount of to the coagulum associated thrombocytes are measured after enzymatic degradation of the coagulum.



13. Reagent for analysis of coagulative, fibrinolytic or haemostatic activity in a biological fluid, especially blood or blood plasma, from a mammalian individual, especially human, characterized in that it is composed of suspended or support-attached endothelial cells or outer membranes from such cells.

14. Reagent according to Claim 13, characterized in that the endothelial cells or their outer membranes are from an individual of the same species as the individual whose biological fluid is to be analyzed, preferably from the same individual and most preferably from the part of the body which is subjected to said analysis.

15. Reagent according to Claim 13 or 14, characterized in that the endothelial cells or their outer membranes are immobilized on a solid phase.

16. Reagent according to any one of the Claims 13-15, characterized in that the endothelial cells or their outer membranes are covalently bound to polyethylene ethers or polysaccharides.

17. Kit for performing a method of analysis of coagulative, fibrinolytic or haemostatic activity in a biological fluid, especially blood or blood plasma, from a mammalian individual, especially human, characterized in that it comprises, as coagulation reagent, a reagent according to any one of the Claims 13-16 and instructions for performing said method.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/01324

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: G01N 33/86, C12Q 1/56

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: G01N, C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, BIOSIS, EMBASE, WPI, WPIL, US PATENT FULLTEXT DATABASES, CA

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9300989 A1 (HAFSLUND NYCOMED AS), 21 January 1993 (21.01.93), page 2, line 37 - page 3, line 7; page 4, line 10 - line 14; page 9, line 19 - line 27, page 12, line 30 --	1-17
A	THROMBOSIS AND HAEMOSTASIS, Volume 60, No 2, 1988, Jerome M. Teitel et al, "The Endothelial Cell and the Factor VIII Bypassing Activity of Prothrombin Complex Concentrate", page 226 - page 229, see page 226, line 38 - line 42, page 228, line 1 - line 2 --	1-17
A	SE 464135 B (KABIVITRUM AB), 11 March 1991 (11.03.91), page 7, line 22 - line 36 --	1-5,7-8

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*Z\* document member of the same patent family

Date of the actual completion of the international search

8 February 1996

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Date of mailing of the international search report

12 -04- 1996

Authorized officer

Carolina Palmcrantz  
Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/01324

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4097238 A (SHELDON J. ASHLEY), 27 June 1978 (27.06.78), column 1, line 59 - line 68	1-12
A	EP 0347933 A2 (RESEARCH CORPORATION TECHNOLOGIES, INC.), 27 December 1989 (27.12.89)	1-7, 9-12

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE95/01324

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See extra sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐  
☐

- The additional search fees were accompanied by the applicant's protest.  
No protest accompanied the payment of additional search fees.

Initially, all the subject matters were included in the search. However, it soon became obvious that pertinent prior art exists making it necessary to reconsider the technical relationship between the different solutions revealed in the claims. This prior art being:

WO 9300989 A1 (document A) and Thrombosis and Haemostasis 60 (2), 226-229, 1988, Teitel JM et. al. "The Endothelial Cell and the Factor VIII Bypassing Activity of Prothrombin Complex Concentrate" (document B).

Document A reveals that human endothelial cells have been used, as a procoagulant, in analysing thrombogenesis in simulated blood vessels.

Document B reveals that fixed endothelial cells can acquire procoagulant activity to a much-greater degree than viable endothelial cells.

Thus, the state of the art illustrates that human endothelial cells (which may be fixed) have been used for in vitro analysis of coagulative activity.

A search for a strict new common concept of invention fails and claim 1 as well as several of the independent claims represent independent subject matter forming lack of unity with each other.

The International Searching Authority has arrived at a principle of division based on the prior art:

Invention 1, claims 1-5 (p), 7 (p), 8 and 13-17, concerns an analysis for coagulative, fibrinolytic or hemostatic activity wherein a biological fluid, e.g. blood, is brought into contact with fixed endothelial cells in vitro. The rate of clot formation is determined and compared with a reference value.

Invention 2, claims 1-7 (p), 9-12 (p) and 13-17, concerns an analysis for coagulative, fibrinolytic or hemostatic activity wherein a biological fluid, e.g. blood, is brought into contact with fixed endothelial cells in vitro. The coagulative processes are disrupted and the amount of coagulated material formed during a given time is determined and compared with a reference value.

Invention 3, claims 1-6 (p), 9-12 (p) and 13-17, concerns an analysis for coagulative, fibrinolytic or hemostatic activity wherein a biological fluid, e.g. blood, is brought into contact with fixed endothelial cells in vitro. The coagulative processes are disrupted after a given time whereafter the amount of dissolved coagulated material after an additional given reaction time is determined and compared with a reference value.

Invention 4, claims 1-6 (p), 9-12 (p) and 13-17, concerns an analysis for coagulative, fibrinolytic or hemostatic activity wherein a biological fluid, e.g. blood, is brought into contact with fixed endothelial cells in vitro. The coagulative processes are disrupted after a given time whereafter the amount of remaining coagulated material after an additional given reaction time is determined and compared with a reference value.

p=partially

The International Searching Authority has decided to invite the applicant to pay one additional search fee for inventions 2-4. This decision is based on the estimated additional search effort. Formally, however the claims are considered to comprise four separate concepts.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

05/02/96

International application No.

PCT/SE 95/01324

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO-A1-	9300989	21/01/93	AT-T- 126722	15/09/95
			AU-A- 2320992	11/02/93
			CA-A- 2112681	21/01/93
			DE-D- 69204288	00/00/00
			EP-A,B- 0592596	20/04/94
			SE-T3- 0592596	
			JP-T- 6509414	20/10/94
			NO-A,D- 934900	01/03/94
SE-B-	464135	11/03/91	AT-T- 127853	15/09/95
			AU-A- 6053390	22/02/91
			CA-A- 2063564	15/01/91
			DE-D- 69022425	00/00/00
			EP-A,B- 0486515	27/05/92
			SE-T3- 0486515	
			JP-T- 4506603	19/11/92
			SE-A- 8902532	15/01/91
			US-A- 5439802	08/08/95
			WO-A- 9101382	07/02/91
US-A-	4097238	27/06/78	NONE	
EP-A2-	0347933	27/12/89	SE-T3- 0347933	
			AT-T- 111532	15/09/94
			DE-D,T- 68918170	02/03/95
			ES-T- 2060698	01/12/94
			JP-A- 2112763	25/04/90
			PT-B- 90941	30/11/94
			US-A,B- 5206140	27/04/93

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**